



## ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2024 - GENERELL INFORMASJON

### Enheten

Organisasjonsnummer: 922 215 871  
Organisasjonsform: Norskreg. utenlandsk foretak  
Foretaksnavn: JAZZ PHARMACEUTICALS DENMARK APS  
NUF  
Forretningsadresse: Kampmannsgade 2  
DK-1604 KØBENHAVN V

### Regnskapsår

Årsregnskapets periode: 01.01.2024 - 31.12.2024

### Konsern

Morselskap i konsern: Nei

### Regnskapsregler

Regler for små foretak benyttet: Ja  
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

### Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Kamilla Have  
Dato for fastsettelse av årsregnskapet: 25.06.2025

### Grunnlag for avgivelse

År 2024: Årsregnskapet er elektronisk innlevert  
År 2023: Tall er hentet fra elektronisk innlevert årsregnskap fra 2024

*Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.*

Brønnøysundregistrene, 06.08.2025



### Resultatregnskap

Beløp i: DKK	Note	2024	2023
<b>RESULTATREGNSKAP</b>			
<b>Inntekter</b>			
Gross profit		36 708 802	31 680 176
<b>Sum inntekter</b>		<b>36 708 802</b>	<b>31 680 176</b>
<b>Kostnader</b>			
Staff cost	2	34 350 235	29 546 059
<b>Sum kostnader</b>		<b>34 350 235</b>	<b>29 546 059</b>
<b>Driftsresultat</b>		<b>2 358 567</b>	<b>2 134 117</b>
<b>Finansinntekter og finanskostnader</b>			
Financial Income	3	353 137	136 682
<b>Sum finansinntekter</b>		<b>353 137</b>	<b>136 682</b>
Financial costs	4	711 093	654 891
<b>Sum finanskostnader</b>		<b>711 093</b>	<b>654 891</b>
<b>Netto finans</b>		<b>-357 956</b>	<b>-518 209</b>
<b>Resultat før skattekostnad</b>		<b>2 000 611</b>	<b>1 615 908</b>
Skattekostnad		462 397	1 020 732
<b>Årsresultat</b>		<b>1 538 214</b>	<b>595 176</b>
<b>Overføringer og disponeringer</b>			
Overføringer til/fra annen egenkapital		1 538 215	595 176
<b>Sum overføringer og disponeringer</b>		<b>1 538 215</b>	<b>595 176</b>



### Balanse

Beløp i: DKK	Note	2024	2023
<b>BALANSE - EIENDELER</b>			
<b>Anleggsmidler</b>			
<b>Immaterielle eiendeler</b>			
Sum anleggsmidler		0	0
<b>Omløpsmidler</b>			
<b>Varer</b>			
Varer		6 774 428	5 786 105
Sum varer		6 774 428	5 786 105
<b>Fordringer</b>			
Kundefordringer		9 817 812	10 931 186
Other receivables		1 376 912	2 024 121
Corporation Tax		481 557	0
Prepayments		1 618 617	893 945
Deffered tax		1 269 995	741 781
Konsernfordringer		5 867 353	10 046 810
Sum fordringer		20 432 246	24 637 843
<b>Bankinnskudd, kontanter og lignende</b>			
Bankinnskudd, kontanter og lignende		5 245 824	5 657 450
Sum bankinnskudd, kontanter og lignende		5 245 824	5 657 450
Sum omløpsmidler		32 452 498	36 081 398
<b>SUM EIENDELER</b>		<b>32 452 498</b>	<b>36 081 398</b>
<b>BALANSE - EGENKAPITAL OG GJELD</b>			
<b>Egenkapital</b>			
<b>Innskutt egenkapital</b>			
Selskapskapital		50 000	50 000
Sum innskutt egenkapital		50 000	50 000



## Balanse

<b>Beløp i: DKK</b>	<b>Note</b>	<b>2024</b>	<b>2023</b>
<b>Opptjent egenkapital</b>			
Annen egenkapital		12 245 111	10 706 897
<b>Sum opptjent egenkapital</b>		<b>12 245 111</b>	<b>10 706 897</b>
<b>Sum egenkapital</b>		<b>12 295 111</b>	<b>10 756 897</b>
<b>Sum langsiktig gjeld</b>		<b>0</b>	<b>0</b>
<b>Kortsiktig gjeld</b>			
Leverandørgjeld		7 307 736	4 982 594
Betalbar skatt		40 610	98 884
Kortsiktig konserngjeld		91 741	12 324 487
Other payable		12 717 300	7 918 536
<b>Sum kortsiktig gjeld</b>		<b>20 157 387</b>	<b>25 324 501</b>
<b>Sum gjeld</b>		<b>20 157 387</b>	<b>25 324 501</b>
<b>SUM EGENKAPITAL OG GJELD</b>		<b>32 452 498</b>	<b>36 081 398</b>



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

**Jazz Pharmaceuticals Denmark ApS**

Kampmannsgade 2  
1604 København V

CVR no. 39 79 14 47

**Annual report for 2024**

(6th Financial year)

Adopted at the annual general meeting  
on 30 June 2025

DocuSigned by:

*David Spackman*

---

David James Spackman  
chairman



Docusign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Table of contents

	Page
<b>Statements</b>	
Statement by management on the annual report	1
Independent auditor's report	2
<b>Management's review</b>	
Company details	5
Management's review	6
<b>Financial statements</b>	
Income Statement	7
Balance Sheet	8
Statement of changes in equity	10
Accounting policies	11
Notes	11



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

### Statement by management on the annual report

The executive board has today discussed and approved the annual report of Jazz Pharmaceuticals Denmark ApS for the financial year 1 January - 31 December 2024.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2024 and of the results of the company's operations for the financial year 1 January - 31 December 2024.


In our opinion, management's review includes a fair review of the matters dealt with in the management's review.

Management recommends that the annual report should be approved by the company in general meeting.

Copenhagen, 30 June 2025

**Executive board**

DocuSigned by:  
  
DB4352FAA945473  
David James Spackman  
Managing Director

DocuSigned by:  
  
21574EE685424FB...  
Kamilla Enggard Have  
Director



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## **Independent auditor's report**

### **To the shareholders of Jazz Pharmaceuticals Denmark ApS**

#### **Opinion**

We have audited the financial Statements of Jazz Pharmaceuticals Denmark ApS for the financial year 1 January - 31 December 2024 comprising, income statement, balance sheet and notes including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's assets, liabilities and financial position at 31 December 2024, and of the results of the company's operations for the financial year 1 January - 31 December 2024 in accordance with the Danish Financial Statements Act.

#### **Basis for Opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements and the IESBA Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Management's responsibility for the financial statements**

Management is responsible for the preparation of financial statements, that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

#### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Independent auditor's report

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- conclude on the appropriateness of management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Statement on management's review

Management is responsible for management's review.

Our opinion on the financial statements does not cover the management's review, and we do not express any form of assurance conclusion thereon.



Docusign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

### Independent auditor's report

In connection with our audit of the financial statements, our responsibility is to read the management's review and, in doing so, consider whether the management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management's review.

Aarhus C, 30 June 2025

CVR no. 25 57 81 98

KPMG

Michael E.K. Rasmussen

State Authorized Public Accountant

MNE no. mne41364



Docusign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Company details

### The company

Jazz Pharmaceuticals Denmark ApS  
Kampmannsgade 2  
1604 København V

CVR no.: 39 79 14 47

Reporting period: 1 January - 31 December 2024

Incorporated: 17 august 2018

Domicile: Copenhagen

### Executive board

David James Spackman, Managing Director  
Kamilla Enggard Have, Director

### Auditors

KPMG  
Statsautoriseret Partnerselskab  
Frederiks Plads 42, 7  
8000 Aarhus C



Docusign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## **Management's review**

### **Business review**

The purpose of the company is promotion, distribution and sale of pharmaceutical products and services, including all activity deemed relevant by the management of the company.

### **Financial review**

The company's income statement for the year ended 31. december 2024 shows a profit of DKK 1,538,214, and the balance sheet at 31 December 2024 shows equity of DKK 12,295,111.

### **Significant events occurring after the end of the financial year**

No events have occurred after the balance sheet date which could significantly affect the company's financial position.



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Income statement 1 January 2024 - 31 December 2024

	Note	2024 DKK	2023 DKK
<b>Gross profit</b>		<b>36,708,802</b>	<b>31,680,176</b>
Staff costs	2	-34,350,235	-29,546,059
<b>Profit before net financials</b>		<b>2,358,567</b>	<b>2,134,117</b>
Financial income	3	353,137	136,682
Financial costs	4	-711,093	-654,891
<b>Profit before tax</b>		<b>2,000,611</b>	<b>1,615,908</b>
Tax on profit for the period		-462,397	-1,020,732
<b>Profit for the year</b>		<b>1,538,214</b>	<b>595,176</b>
<b>Recommended appropriation of profit/loss</b>			
Retained earnings		1,538,214	595,176
		<b>1,538,214</b>	<b>595,176</b>



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Balance sheet at 31 December 2024

	<u>Note</u>	<u>2024</u>	<u>2023</u>
		DKK	DKK
<b>Assets</b>			
Finished goods and goods for resale		6,774,428	5,786,105
<b>Stocks</b>		<b>6,774,428</b>	<b>5,786,105</b>
Trade receivables		9,817,812	10,931,186
Receivables from group enterprises		5,867,353	10,046,810
Other receivables		1,376,912	2,024,121
Deferred tax asset		1,269,995	741,781
Corporation tax		481,557	0
Prepayments		1,618,617	893,945
<b>Receivables</b>		<b>20,432,246</b>	<b>24,637,843</b>
<b>Cash at bank and in hand</b>		<b>5,245,824</b>	<b>5,657,450</b>
<b>Total current assets</b>		<b>32,452,498</b>	<b>36,081,398</b>
<b>Total assets</b>		<b>32,452,498</b>	<b>36,081,398</b>



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Balance sheet at 31 December 2024

	<u>Note</u>	<u>2024</u>	<u>2023</u>
		DKK	DKK
<b>Equity and liabilities</b>			
Share capital		50,000	50,000
Retained earnings		<u>12,245,111</u>	<u>10,706,897</u>
<b>Equity</b>		<u><b>12,295,111</b></u>	<u><b>10,756,897</b></u>
Trade payables		7,307,736	4,982,594
Payables to group enterprises		91,741	12,324,487
Corporation tax		40,610	98,884
Other payables		<u>12,717,300</u>	<u>7,918,536</u>
<b>Total current liabilities</b>		<u><b>20,157,387</b></u>	<u><b>25,324,501</b></u>
<b>Total liabilities</b>		<u><b>20,157,387</b></u>	<u><b>25,324,501</b></u>
<b>Total equity and liabilities</b>		<u><b>32,452,498</b></u>	<u><b>36,081,398</b></u>
Contingent liabilities	5		
Related parties and ownership structure	6		



Docusign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

### Statement of changes in equity

	Share capital	Retained earnings	Total
Equity at 1 January 2024	50,000	10,706,897	10,756,897
Net profit for the year	0	1,538,214	1,538,214
<b>Equity at 31 December 2024</b>	<b>50,000</b>	<b>12,245,111</b>	<b>12,295,111</b>



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Notes

### 1 Accounting policies

The annual report of Jazz Pharmaceuticals Denmark ApS for 2024 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, as well as provisions applying to reporting class C entities.

The accounting policies applied are consistent with those of last year.

The annual report for 2024 is presented in DKK

### Income statement

#### Revenue

Income from the sale of goods for resale is recognised in the income statement, provided that the transfer of risk, usually on delivery to the buyer, has taken place and that the income can be measured reliably and is expected to be received.

#### Other operating income

The item Other operating income includes items of a secondary nature relative to the company's activities, including management recharges.

#### Other external costs

Other external costs include expenses related to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

#### Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts relating to the financial period. Net financials include interest income and expenses, realised and unrealised exchange gains and losses on foreign currency transactions and surcharges and allowances under the advance-payment-of-tax scheme, etc.

#### Tax on profit for the period

Tax for the period, which comprises the current tax charge for the period and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit for the period and directly in equity as regards the portion that relates to entries directly in equity.

### Balance sheet

#### Leases

All leases are operating leases. Payments relating to operating leases and any other leases are recognised in the income statement over the term of the lease. The company's total liabilities relating to operating leases and other rent agreements are disclosed under 'Contingencies, etc.'

#### Stocks

Stocks are measured at cost using the FIFO method. Where the net realisable value is lower than the cost, inventories are recognised at this lower value.



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Notes

### 1 Accounting policies (continued)

The cost of goods for resale, raw materials and consumables comprises the purchase price plus delivery costs.

#### Receivables

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable is impaired, an impairment loss for that individual asset is recognised.

#### Prepayments

Prepayments recognised under 'Current assets' comprises expenses incurred concerning subsequent financial years.

#### Equity

##### Dividends

Proposed dividends are disclosed as a separate item under equity. Dividends are recognised as a liability when declared by the annual general meeting of shareholders.

#### Income tax and deferred tax

Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account.

Deferred tax is measured according to the liability method in respect of temporary differences between the carrying amount of assets and liabilities and their tax base, calculated on the basis of the planned use of the asset and settlement of the liability, respectively. Deferred tax is measured at net realisable value.

#### Liabilities

Liabilities, which include trade payables, payables to group entities and other payables, are measured at amortised cost, which is usually equivalent to nominal value.

#### Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses.



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Notes

### 1 Accounting policies (continued)

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose, or was recognised in the latest financial statements, is recognised in the income statement as financial income or financial expenses.



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Notes

	<u>2024</u>	<u>2023</u>
	DKK	DKK
<b>2 Staff costs</b>		
Wages and salaries	30,059,824	25,819,127
Pensions	2,387,446	2,219,797
Other social security costs	<u>1,902,965</u>	<u>1,507,135</u>
	<b><u>34,350,235</u></b>	<b><u>29,546,059</u></b>
Number of fulltime employees on average	<u>18</u>	<u>17</u>
<b>3 Financial income</b>		
Interest received from group enterprises	86,540	29,020
Other financial income	<u>266,597</u>	<u>107,662</u>
	<b><u>353,137</u></b>	<b><u>136,682</u></b>
<b>4 Financial costs</b>		
Interest paid to group enterprises	206,217	490,042
Other financial costs	<u>504,876</u>	<u>164,849</u>
	<b><u>711,093</u></b>	<b><u>654,891</u></b>

## 5 Contingent liabilities

The company has entered into car lease agreements with a contingent liability of TDKK 648.

The company has entered into a tenancy agreement with a contingent liability of TDKK 170.



DocuSign Envelope ID: 3FEE0CCA-BAFF-48DA-9570-6874985E0262

## Notes

### **6 Related parties and ownership structure**

#### **Controlling interest**

Jazz Pharmaceuticals Denmark ApS' related parties comprise of the following:

Jazz Pharmaceuticals Denmark ApS is part of the consolidated financial statements of Jazz Pharmaceuticals Ireland Holdings Limited, Dublin Ireland, which is the smallest group in which the Company is included as a subsidiary.